Picture of Shustov
Professor of Medicine, Division of Hematology
University of Washington School of Medicine
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center

Faculty Information


Dr. Shustov's research is focused on development of novel therapeutic strategies and implementation of targeted biologic agents into treatment paradigms of peripheral T-cell lymphomas and cutaneous T-cell lymphomas. In addition, he dedicates a lot of his activities in developing national and international collaborations to study these rare lymphoid tumors.

Active Clinical Trials:

A Phase 1, Dose-Finding Study of Folotyn ® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)

A Phase 2 study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for the treatment of T-cell Non-Hodgkin Lymphoma

A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn ® (Pralatrexate Injection) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

A phase 1 dose finding study of brentuximab vedotin in combination with ceritinib in patients with newly diagnosed ALK-positive Anaplastic Large Cell Lymphoma.

A phase 2 clinical trial of romidepsin and oral azacitidin in patients with relapsed and refractory peripheral T-cell lymphomas.

Education & Training: 
Crimea Medical Institute
Simferopol, Ukraine
Critical Care Medicine Residency
Department of Critical Care and Anesthesiology, Crimea Medical Institue Medical Center
Simferopol, Ukraine
Post-doctoral Research Fellow
Division of Rheumatology and Clinical Immunology, University of Maryland
Baltimore, MD
Residency, Internal Medicine
York Hospital
York, PA
Hematology/Oncology Fellow
University of Washington/Fred Hutchinson Cancer Research Center
Seattle, WA